Skip to content

Erasca, Inc. ERAS Accrued Expenses

Accrued Expenses at other companies

Eli Lilly logo
Eli LillyLLY
$1.36B+22.0%
Amgen logo
AmgenAMGN
$16.58B-3.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$3.24M+1.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$43.75M+32.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$19M+11.8%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$847K-49.6%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s accrued expenses?
Erasca, Inc. (ERAS) reported accrued expenses of $19.25M in Q1 2026.
How has Erasca, Inc.'s accrued expenses changed year-over-year?
Erasca, Inc.'s accrued expenses increased by 4.5% year-over-year, from $18.42M to $19.25M.
What is the long-term trend for Erasca, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), Erasca, Inc.'s accrued expenses has grown at a 13.5% compound annual growth rate (CAGR), from $11.93M to $22.46M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.